Supplementary Figures

List of supplementary figures:

Figure S1: Effect of anti-FH mAbs in the sheep erythrocyte hemolytic assay.

Figure S2: Epitope mapping and cross-reactivity of anti-FH.07.

Figure S3: Inhibition of complement-mediated hemolysis of sheep erythrocytes by anti-FH.07 or eculizumab in *CFHR1*$^{-/-}$ serum.

Figure S1



Figure S1. Effect of anti-FH mAbs in the sheep erythrocyte hemolytic assay. Sheep erythrocytes (E_S) were incubated in 10% (v/v) normal human serum with the indicated mAbs at 37°C for 75 minutes. Hemolysis was measured as absorbance at 412 nm, corrected for background absorbance measured at 690 nm and expressed as percentage of the control lysis (E_S incubated with 0.6% (w/v) saponin). Data are presented as mean with standard deviation (n=2).

Figure S2



Figure S2. Epitope mapping and cross-reactivity of anti-FH.07. (**A**) Binding of ^{125}I-labeled FH and fragments of FH to anti-FH.07 was assessed by radioimmunoassay (RIA). Percentage binding was calculated based on the total input. (**B**) ELISA-based competition assay using biotinylated FH and unbiotinylated FH or FH fragments. Binding of biotinylated FH in the presence of 100-fold excess of indicated competitors, determined by ELISA. (**C**) Binding of biotinylated FH or recombinant FHR proteins to anti-FH.07, determined by ELISA.

Figure S3



Figure S3. Inhibition of complement-mediated hemolysis of sheep erythrocytes by anti-FH.07 or eculizumab in *CFHR1*$^{-/-}$ serum. Sheep erythrocyte (E_S) hemolysis was induced with anti-FH.09, using either a NHS pool or a pool of sera from 4 healthy donors with a homozygous deletion of *CFHR1* (*CFHR1*$^{-/-}$ pool). Anti-FH.07 (**A**) or eculizumab (**B**) were added at indicated concentrations. Horizontal dashed lines indicate 50% of the inhibition. All data (n=3) are presented as mean with standard deviation.